Diabetes
Across
- 4. Brand name of the first oral GLP-1 agonist
- 7. DAPA-HF showed CV risk reduction in patients with HF regardless of whether the patient had diabetes
- 8. Medication to avoid with a personal or family history of bladder cancer
- 9. SGLT2 inhibitor that showed increased risk of amputations in the CANVAS-RENAL Trial
- 10. Average weight loss in pounds seen with Ozempic
Down
- 1. Most common adverse effect of a GLP-1 agonist
- 2. The only DPP-IV inhibitor you do not have to renally dose adjust
- 3. First line treatment for Type 2 diabetes
- 5. Longest acting insulin
- 6. Generic name of empagliflozin